BioXcel Therapeutics Newsroom

Hold Rating on Bioxcel Therapeutics Amid Growth Potential and Financial Uncertainties

TipRanksMay 14 05:07 ET

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Earnings Call Transcript

Yahoo FinanceMay 10 11:58 ET

Bullish Outlook: Bioxcel Therapeutics' Revenue Surge and Promising Clinical Trials Fuel Buy Rating

TipRanksMay 10 06:47 ET

Q1 2024 BioXcel Therapeutics Inc Earnings Call

Yahoo FinanceMay 9 23:31 ET

Express News | BioXcel Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results

BenzingaMay 9 12:36 ET

BioXcel Therapeutics, Inc. (BTAI) Q1 2024 Earnings Call Transcript

BioXcel Therapeutics, Inc. (BTAI) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 9 09:53 ET

BioXcel Therapeutics | 10-Q: Quarterly report

Futu NewsMay 9 09:10 ET · Announcements

BioXcel Therapeutics Q1 2024 GAAP EPS $(0.87) Beats $(1.04) Estimate, Sales $582.000K Beat $464.000K Estimate

BioXcel Therapeutics (NASDAQ:BTAI) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of $(1.04) by 16.35 percent. This is a 52.72 percent increase over losses of

BenzingaMay 9 07:11 ET

Express News | BioXcel Therapeutics Reports First Quarter 2024 Financial Results

ReutersMay 9 07:00 ET

Express News | BioXcel Therapeutics Q1 Net Income USD -26.791 Million Vs. Ibes Estimate USD -23.2 Million

ReutersMay 9 07:00 ET

Express News | BioXcel Therapeutics Q1 Revenue USD 582 Thousand Vs. Ibes Estimate USD 464 Thousand

ReutersMay 9 07:00 ET

BioXcel Therapeutics 1Q Loss/Shr 87c >BTAI

BioXcel Therapeutics 1Q Loss/Shr 87c >BTAI

Dow JonesMay 9 07:00 ET

Hold Rating on Bioxcel Therapeutics Amid Strategic and Clinical Trial Uncertainties

TipRanksApr 26 02:11 ET

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024

NEW HAVEN, Conn., April 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in n

BioXcel TherapeuticsApr 25 00:00 ET

BioXcel Therapeutics Announces Late-Breaking Abstract On Preliminary Findings From Phase 2 Investigator-Sponsored Trial Of BXCL701 And KEYTRUDA In Metastatic Pancreatic Ductal Adenocarcinoma Selected For Presentation At 2024 ASCO Annual Meeting

Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ETTrial being led by Georgetown University's Lombardi Comprehensive Cancer CenterNEW HAVEN, Conn., April 24, 2024 (GLOBE N

BenzingaApr 24 10:33 ET

Express News | HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $10 Price Target

Moomoo 24/7Apr 23 06:28 ET

BioXcel Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/23/2024 250.88% HC Wainwright & Co. → $10 Reiterates Buy → Buy 03/18/2024 285.96% HC Wainwright & Co. →

BenzingaApr 23 06:27 ET

Buy Rating Reaffirmed for BioXcel Therapeutics Amidst Expansion Opportunities and FDA-Approved IGALMI

TipRanksApr 23 06:25 ET

Bioxcel Therapeutics Advances SERENITY Trial and Strategy

TipRanksApr 22 07:22 ET

Express News | BioXcel: Expects to Enroll About 30 Patients in Study to Evaluate Correlation Between Patient-Reported Efficacy With Trained Rater-Reported Efficacy

Moomoo 24/7Apr 22 07:06 ET